Early Ablation Treatment for Atrial Fibrillation to Prevent Stroke and Heart Problems in Patients with Multiple Health Conditions

What this Trial Is About

Researchers are investigating whether early atrial fibrillation ablation reduces cardiovascular events in patients with atrial fibrillation who have a high burden of other health problems, measured by a CHA2DS2-VASc score of 4 or more. This is an international, randomized, open trial designed to compare early ablation with usual care to see if it lowers risks of stroke, cardiovascular death, or heart failure events. The study also looks at safety, patient-reported outcomes, and cognitive function in this population. Participants are randomly assigned to one of two groups one group undergoes early atrial fibrillation ablation, specifically pulmonary vein isolation within two months of randomization, while the other group receives usual care following guideline-based treatments tailored to their individual medical needs. All treatments involved are approved therapies. The trial aims to enroll 2312 patients and will continue until a set number of cardiovascular events have occurred, with an estimated average follow-up of about four years. During the study, researchers will monitor cardiovascular complications including death, stroke, and hospitalizations related to heart failure. They will also track serious complications from atrial fibrillation therapy and assess quality of life, heart function, rhythm status, cognitive function, and hospital stays over the follow-up period. Patients will be regularly evaluated for both safety and effectiveness outcomes throughout the study duration.

Early Atrial Fibrillation Ablation for Stroke Prevention in Patients With High Comorbidity Burden (EASThigh-AFNET 11)